Administration of agmatine prior to physical or psychological stress in pregnant mice ameliorates behavioral and cognitive deficits in female offspring
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Administration of agmatine prior to physical or psychological stress in pregnant mice ameliorates behavioral and cognitive deficits in female offspring. / Hassanshahi, Amin; Janahmadi, Mahyar ; Razavinasab, Moazamehosadat ; Ilaghi, Mehran ; Kohlmeier, Kristi Anne; Hassanshahi, Elham ; Shabani, Mohammad.
In: International Journal of Developmental Neuroscience, Vol. 83, No. 5, 2023, p. 442-455.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Administration of agmatine prior to physical or psychological stress in pregnant mice ameliorates behavioral and cognitive deficits in female offspring
AU - Hassanshahi, Amin
AU - Janahmadi, Mahyar
AU - Razavinasab, Moazamehosadat
AU - Ilaghi, Mehran
AU - Kohlmeier, Kristi Anne
AU - Hassanshahi, Elham
AU - Shabani, Mohammad
PY - 2023
Y1 - 2023
N2 - Physical or psychological stress experienced by a mother during gestation is often associated with serious behavioural and cognitive deficits in newborns. Investigations of protective agents, which could prevent the adverse outcomes of prenatal stress (PS), are warranted. Agmatine is a neurotransmitter putatively involved in the physiological response to stress, and exogenous administration of agmatine has been shown to produce a variety of neuroprotective effects. In this study, we aimed to assess whether prenatal agmatine exposure could ameliorate behavioural and cognitive deficits in female offspring born to prenatally stressed mice. Pregnant Swiss Webster (SW) mice were exposed to physical or psychological stress from the 11th to 17th days of gestation. Agmatine (37.5 mg/kg, i.p.) was administrated 30 min before the induction of stress for seven consecutive days. The pups were assessed using a variety of behavioural tests and molecular assays on postnatal days 40 to 47. Agmatine attenuated impairments in locomotor activity, anxiety-like behaviour, and drug-seeking behaviour associated with both physical and psychological PS. Furthermore, agmatine reduced PS-induced impairments in passive avoidance memory and learning. Neither PS nor agmatine treatment affected the mRNA expression level of hippocampal brain-derived neurotrophic factor (BDNF) or tyrosine hydroxylase (TH) in the ventral tegmental area (VTA). Taken together, our findings highlight the protective effects of prenatally administered agmatine on PS-mediated behavioural and cognitive deficits of the offspring. Future studies are needed to elucidate the underlying mechanisms, which could allow for more targeted prenatal treatments.
AB - Physical or psychological stress experienced by a mother during gestation is often associated with serious behavioural and cognitive deficits in newborns. Investigations of protective agents, which could prevent the adverse outcomes of prenatal stress (PS), are warranted. Agmatine is a neurotransmitter putatively involved in the physiological response to stress, and exogenous administration of agmatine has been shown to produce a variety of neuroprotective effects. In this study, we aimed to assess whether prenatal agmatine exposure could ameliorate behavioural and cognitive deficits in female offspring born to prenatally stressed mice. Pregnant Swiss Webster (SW) mice were exposed to physical or psychological stress from the 11th to 17th days of gestation. Agmatine (37.5 mg/kg, i.p.) was administrated 30 min before the induction of stress for seven consecutive days. The pups were assessed using a variety of behavioural tests and molecular assays on postnatal days 40 to 47. Agmatine attenuated impairments in locomotor activity, anxiety-like behaviour, and drug-seeking behaviour associated with both physical and psychological PS. Furthermore, agmatine reduced PS-induced impairments in passive avoidance memory and learning. Neither PS nor agmatine treatment affected the mRNA expression level of hippocampal brain-derived neurotrophic factor (BDNF) or tyrosine hydroxylase (TH) in the ventral tegmental area (VTA). Taken together, our findings highlight the protective effects of prenatally administered agmatine on PS-mediated behavioural and cognitive deficits of the offspring. Future studies are needed to elucidate the underlying mechanisms, which could allow for more targeted prenatal treatments.
U2 - 10.1002/jdn.10277
DO - 10.1002/jdn.10277
M3 - Journal article
C2 - 37269159
VL - 83
SP - 442
EP - 455
JO - International Journal of Developmental Neuroscience
JF - International Journal of Developmental Neuroscience
SN - 0736-5748
IS - 5
ER -
ID: 346042459